This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Commentary|Articles|January 29, 2026
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
Fact checked by: Ron Panarotti
Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.
Advertisement
Advertisement
In this discussion panel with Pharmacy Times, Meredith Pelster, MD, MSCI; Ben Zeskind, PhD; and Igor Matushansky, MD, PhD, discuss Immuneering’s investigational MEK inhibitor atebimetinib and its potential to reshape first-line treatment for pancreatic cancer. The panel reviews phase 2 data showing a 64% overall survival rate at 12 months, representing a meaningful improvement over historical benchmarks in a disease with limited therapeutic progress.
Related to this article
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Advertisement
Advertisement